Value-Based Healthcare
Helping customers create a sustainable, value-based Healthcare Ecosystem.
Dedalus is built on a foundational commitment to help the healthcare industry improve the quality of care and to provide solutions that give healthcare decision makers and patients real time knowledge at the point of care. Dedalus helps Life Sciences organisations deliver on their Clinical Research and Value Based Healthcare goals, allowing our clients to accelerate drug development and to create real,scalable and differentiated digital initiatives that support innovative care and commercial models.
At this moment in time, there is a shift in how Life Sciences and Pharma organisations are approaching the market, there is an impetus and moreover a requirement to move beyond transactional and volume based models towards a more considered, holistic and stakeholder centric approach that is cognisant of the challenges Heathcare currently faces. Value based Healthcare models alongside a firm commitment to delivering a truly customer and patient centred experience is what’s required to excel in the future.
Value-Based Healthcare
Leveraging our extensive healthcare experience and deep expertise in digital healthcare solutions across the Healthcare Ecosystem, provides us with a unique opportunity to identify the unmet needs of the market, and to forge new relationships and propose some truly innovative eHealth solutions and a set of accelerators which are aligned to a wide variety of regional digital healthcare strategies. We work with our clients to co-create the future, working together to develop sustainable Value Based Healthcare models, which are underpinned by a deep understanding of the patient journey and how they typically flow through the care system. The sharing of knowledge and insights across the patient journey provides a mutually beneficial platform where innovative new medicines or treatments can reach the market faster and patients and caregivers benefit from more competitive outcomes-based treatment options.
The authorisation of drugs for the European market has been focused in the past exclusively on the criteria of safety and efficacy.
Outcome Based Agreements are tools to facilitate patient access to new medicines and health technologies, especially in Oncology and Rare diseases, through faster coverage decisions, while managing uncertainty related to the performance and/or budget impact of such products.
The introduction of electronic medical records in many countries would likely be of considerable help in compiling the necessary data to underpin such decision making.
Pharmaceutical companies need to prepare for the increasing role that digital health technology will play in their businesses, including Managed Entry Agreements.
Dedalus is helping its clients by facilitating data management from EHRs or other Health Information Systems supporting Outcome Based Agreements, by providing:
- specific Country/Region expertise in Healthcare Information Systems and data interoperability, serving National, Regional and Local Healthcare Providers;
- a set of Digital Health Accelerators that support the management of data involved in these types of agreements;
- health data mapping to OMOP data models for facilitating information sharing to Health Authorities and Payers.
Key Benefits
- Support management of a price scheme based on the information collected.
- Automating RWD database for medicament administration at a patient level.
Key features
- Automatic extraction of necessary data from EHR or other HIS.
- Healthcare Data Tagging.
- Transformation Layer to map EHR data to Drug Exposure, Demographics, Condition and Care Site OMOP CDM.
- Canonic Ontology harmonising FHIR and OMOP Standards.
- Cohort Builder for Population Studies.
- Population Level Estimation Predictive Models.
- Patient Level Estimation predictive models.
- Data anonymisation or pseudonymisation.
The traditional operating model for Life Sciences Organisations is not sustainable anymore. They need to overcome the biggest barriers for translational research- to understand real healthcare patient journeys. Patients nowadays expect a new Healthcare model where prevention and proactive intervention are fundamental and integral to delivering healthcare services of the future.
There is a clear need to collaborate and share knowledge for the advancement of public health. Life Science and Pharma companies are turning to Technology and digital experts for support to transform. The ability of Life Science and Pharmaceutical companies to positively impact patient care through the development of innovative solutions, is paramount to their success in driving engagement and positive outcomes which in turn fuel their growth and R&D strategies for the future.
Dedalus can support on:
- co -Development and real scalability of Digital Health Solutions, that can enhance Clinical Research and Value based Healthcare initiatives.
- adoption of Pharma proprietary or Start Ups digital solutions to facilitate integration with Health Information systems and routine Clinical Workflows.
Key Benefits
- Implementation and scalability of eHealth solutions without Big-Bangs.
- Deploy innovative solutions in retro-compatibility with existing ones.
- Facilitate eHealth for Patient Support Programs.
- Supporting clinical pathways across the care continuum.
- HCP Connectivity for Companion Therapeutic.
- Facilitate HCPs connectivity with timely alerts enabling prevention and treatment optimisation.
- Partnering with a GDPR DNA company.
Key features
- Data anonymisation or pseudonymisation.
- Standard and customised integration with Clinical Decision Support System.
- Stand alone or integrated Telehealth Platform (Connectivity HL7 – FHIR).
- Telehealth accelerators linked with EHRs for Medical Appointment and others.
- Dedalus proprietary Patient Access App.
- eHealth accelerators for interoperability with Clinical Research.